复发或难治性滤泡淋巴瘤治疗方案的药物经济学研究综述

摘要/Abstract

摘要： 目的：通过对2010年1月至2022年5月发表的复发或难治性滤泡淋巴瘤药物经济学研究进行总结及分析，旨在为该领域创新药物的经济学评价提供方法学参考。方法：检索Medline、Embase数据库以及HTA机构官网，筛选出复发或难治性滤泡淋巴瘤药物经济学研究，综合分析其模型结构、参数来源、对照选择等因素。结果：共纳入14篇国外文献，以构建3种健康状态马尔科夫模型进行成本效用分析为主要的研究方法。结论：对照品、模型结构及疗效数据外推方法可能是未来复发或难治性滤泡淋巴瘤治疗方案药物经济学研究的关键影响因素，需结合临床实际和试验数据成熟程度谨慎选择。

关键词: font-size:medium, ">复发或难治性滤泡淋巴瘤；药物经济学

Abstract: Objective：To summarize and analyze the pharmacoeconomic studies of relapsed or refractory follicular lymphoma(RR-FL) published from January 2010 to May 2022， in order to provide a methodological recommendation for the economic evaluation of innovative drugs in this field. Methods：Medline， Embase databases and the official website of the HTA institution were searched to screen out the pharmacoeconomic studies of RR-FL， and comprehensively analyzed the model structure， parameter source， control selection and other factors. Results： A total of 14 foreign literatures were included， and the main evaluationmethod was to construct a three-health status Markov model for cost-utility analysis. Conclusion：The comparator， model structure and extrapolation method of efficacy data may be the key factors for the future pharmacoeconomic evaluation on treatment of RR-FL， which should be carefully selected based on clinical reality and the maturity of experimental data.

Key words: font-size:medium, ">Relapsed/Refractory Follicular Lymphoma；Pharmacoeconomics

中图分类号:

高鑫, 陈丽萍, 宣建伟. 复发或难治性滤泡淋巴瘤治疗方案的药物经济学研究综述[J]. 中国药物评价, 2022, 39(6): 509-514.

GAO Xin, CHEN Li-ping, XUAN Jian-wei. Review of Pharmacoeconomic Evaluation on Treatment of Relapsedor Refractory Follicular Lymphoma[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(6): 509-514.

参考文献

[1]Sung H， Ferlay J， Siegel RL， et al.Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin，2021，71(3)：209-249.
     [2]黄慧强.中国滤泡性淋巴瘤诊断与治疗指南(2020年版)[J].中华血液学杂志，2020，41(7)：537-544.
     [3]Johnson PW， Rohatiner AZ， Whelan JS， et al.Patterns of survival in patients with recurrent follicular lymphoma： a 20-year study from a single center[J].J Clin Oncol，1995，13(1)：140-147.
     [4]Rivas-Delgado A， Magnano L， Moreno-Velázquez M， et al.Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era[J].Br J Haematol，2019，184(5)：753-759.
     [5]林志娟，徐兵.复发难治滤泡淋巴瘤治疗进展[J].白血病·淋巴瘤，2022，31(1)：16-19.
     [6]邱立华，郑雅心，张志蓉，等.滤泡淋巴瘤免疫靶向治疗研究进展[J].中国实验血液学杂志，2022，30(2)：627-630.
     [7]Roche. Obinutuzumab advice. Obinutuzumab 1，000 mg concentrate for solution for infusion(Gazyvaro）SMC No.(1219/17)[R]. Glasgow：SMC， 2017
     [8]Erdogan-Ciftci E， Yanik L， Akyol Ersoy B， et al.Cost effectiveness of obinutuzumab plus bendamustine vs bendamustine alone for patients who did not respond or progressed during or after rituximab or a rituximab containing regiment in turkey[J].Value in Health，2019，22：S481.
     [9]Vandekerckhove S， Lamotte M， Iannazzo S， et al.Cost utility analysis of bortezomib in a biomarker positive subgroup of relapsed and refractory folicular lymphoma[J].Value in Health，2012，15(7)：A427.
     [10]Deconinck E， Miadi-Fargier H， Pen CL， et al.Cost effectiveness of rituximab maintenance therapy in follicular lymphoma： long-term economic evaluation[J].Pharmacoeconomics，2010，28(1)：35-46.
     [11]Soini EJO， Martikainen JA， Nousiainen T.Treatment of follicular non-Hodgkin′s lymphoma with or without rituximab： Cost-effectiveness and value of information based on a 5-year follow-up[J].Annals of Oncology，2011，22(5)：1189-1197.
     [12]Blommestein HM， Issa DE， Pompen M， et al.Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma： results of a population-based study[J].Eur J Haematol，2014，92(5)：398-406.
     [13]Gilead. Idelalisib， 100mg and 150mg film-coated tablets(Zydelig) SMC No.(1039/15)[R]. Glasgow：SMC， 2015
     [14]Gilead.Final economic guidance report. Idelalisib(zydelig) for follicular lymphoma[R]. Ottawa：CADTH， 2016
     [15]Guzauskas GF， Masaquel A， Reyes C， et al.What is the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US[J].Blood，2016，128：22.
     [16]Roche.Initial economic guidance report： obinutuzumab(gazyva) for follicular lymphoma[R]. Ottawa：CADTH， 2017.
     [17]Guzauskas GF， Masaquel A， Reyes C， et al.Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US[J].Journal of Medical Economics，2018，21(10)：960-967.
     [18]Haukaas FS， Ohna A， Krivasi T.Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway[J].Applied Health Economics and Health Policy，2018，16(4)：569-577.
     [19]Roche. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab(CDF Review of TA472) [ID1583][R]. NICE，2020.
     [20]Vijenthira A， Kuruvilla J， Prica A.Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy[J].Bone Marrow Transplant， 2021，56(10)：2400-2409.
     [21]Sehn LH， Chua N， Mayer J， et al.Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma(GADOLIN)： a randomised， controlled， open-label， multicentre， phase 3 trial[J].Lancet Oncol，2016，17(8)：1081-1093.
     [22]Van Oers MH， Klasa R， Marcus RE， et al.Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction： results of a prospective randomized phase 3 intergrouptrial[J].Blood，2006，108(10)：3295-3301.
     [23]Gopal AK， Kahl BS， de Vos S， et al.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma[J].N Engl J Med，2014，370(11)：1008-1018.
     [24]Pettengell R， Donatti C， Hoskin P， et al.The impact of follicular lymphoma on health-related quality of life[J].Annals of Oncology，2008，19(3)：570-576.
     [25]Wild D， Walker M， Pettengell R， et al.Utility elicitation in patients with follicular lymphoma[J].Value in Health，2006，9(6)：A294.
     [26]Gilead.Idelalisib for treating refractory follicular lymphoma [TA604][R].London：NICE， 2018.
     [27]Casulo C， Larson MC， Lunde JJ， et al.Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy(LEO CReWE)： a multicentre cohort study[J].The Lancet Haematology，2022，9(4)：e289-e300.
     [28]Davé K， Strunz-McKendry T， Felizzi F， et al.Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma[J].Value in Health，2020，23：S466.
     [29]Williams C， Lewsey JD， Mackay DF， et al.Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses： A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling[J].Med Decis Making，2017，37(4)：427-439.